circZBTB44通过调控AKT通路促进肾透明细胞癌增殖和迁移的研究

目的 探究circZBTB44在肾透明细胞癌中的表达情况及探讨circZBTB44在肾透明细胞癌中的生物学功能及促进肾透明细胞癌细胞进展的可能机制。方法 通过qRT-PCR法检测circZBTB44在我院21对肾透明细胞癌组织及细胞系786-O、ACHN中的表达水平;通过放线菌素D实验、RNase R实验、核浆分离实验鉴定circZBTB44的特征;通过siRNA下调circZBTB44的表达后,通过MTS细胞增殖实验、克隆形成实验及Transwell迁移实验来探究circZBTB44对肾透明细胞癌786-O、ACHN的生物学功能影响;通过蛋白免疫印迹实验来探究circZBTB44调控的下游通路。结果 circZBTB44在肾透明细胞癌组织和细胞株786-O和ACHN中明显高表达。下调circZBTB44的表达可明显抑制786-O和ACHN的增殖和迁移能力。下调circZBTB44可抑制肾透明细胞癌786-O和ACHN细胞中AKT的磷酸化。结论 circZBTB44在肾透明细胞癌中高表达。circZBTB44可能通过调控AKT信号通路促进肾透明细胞癌的增殖和迁移。     

Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer

Plasminogen activator inhibitor (PAI)-1 is predictive of poor outcome in several types of cancer. The present study investigated the biological role for PAI-1 in ovarian cancer and potential of targeted pharmacotherapeutics. In patients with ovarian cancer, PAI-1 mRNA expression in tumor tissues was positively correlated with poor prognosis. To determine the role of PAI-1 in cell proliferation in ovarian cancer, the effects of PAI-1 inhibition were examined in PAI-1-expressing ovarian cancer cells. PAI-1 knockdown by small interfering RNA resulted in significant suppression of cell growth accompanied with G2/M cell cycle arrest and intrinsic apoptosis. Similarly, treatment with the small molecule PAI-1 inhibitor TM5275 effectively blocked cell proliferation of ovarian cancer cells that highly express PAI-1. Together these results suggest that PAI-1 promotes cell growth in ovarian cancer. Interestingly, expression of PAI-1 was increased in ovarian clear cell carcinoma compared with that in serous tumors. Our results suggest that PAI-1 inhibition promotes cell cycle arrest and apoptosis in ovarian cancer and that PAI-1 inhibitors potentially represent a novel class of anti-tumor agents.     

人工晶状体睫状沟悬吊术缝线改良研究

目的探讨人工晶状体Ⅱ期睫状沟悬吊缝线改良的可行性和实用性。方法选取需Ⅱ期人工晶状体睫状沟悬吊患者32例(32只眼),采用折叠人工晶状体,利用VE2200人工晶状体植入系统,由双针各带有环形10-0非吸收聚丙烯缝线固定于睫状沟,结扎缝线关闭自创的口袋样裂隙状板层巩膜瓣,线结自行埋藏。结果患者术后植入的人工晶状体居中,裸眼视力均有不同程度的提高。术后3个月,视力>0.8的眼3只(9.4%),视力0.4~0.8眼17只(53.1%),视力<0.4的眼12只(37.5%)。术前、术后3个月平均角膜散光均值分别为(1.75±1.24)D与(1.64±1.32)D,差异无统计学意义(P>0.05)。切口闭合线结埋藏满意。结论采用双针10-0聚丙烯缝线睫状沟悬吊固定晶状体、关闭自创口袋样巩膜裂隙状板层瓣、线结埋藏一次完成,操作简捷,手术并发症少,有效可行。     

尤昭玲教授辨证治疗子宫切口假腔三步法

尤昭玲教授认为瘀热、邪毒、气虚是子宫切口假腔形成之根本，临床运用中医辨证治疗主要分三步：非经期以“清宫”为主，经前期以“逼宫”为主，经后期以“缩宫”为主。分别使用自拟内炎方加减，妇科外敷包和假腔方加减。该“三步法”在临床应用中疗效显著。     

罗哌卡因切口周围局部浸润对大鼠慢性术后疼痛的抑制作用

目的 评价术中不同浓度罗哌卡因切口周围局部浸润对慢性术后疼痛的抑制作用. 方法 雄性SD大鼠30只,体重180 g～220 g,按随机数字表法分为5组,每组6只:假手术组(S组)、生理盐水组(R0组)、0.5％罗哌卡因组(R1组)、0.75％罗哌卡因组(R2组)、1％罗哌卡因组(R3组).按Flatters法制作皮肤/肌肉切开牵拉模型(skin/muscle incision and retraction,SMIR),S组大鼠除未进行SMIR之外其他操作均与其他组相同.应用yon Frey细丝法测定术前及术后1、3、7、10、14、17、21、24、28 d的机械缩足反射阈值(paw withdrawal mechanical threshold,PWMT). 结果 各组术前PWMT基础值差异无统计学意义(P＞0.05);与R0组比较,R1组PWMT于术后1、3、7、10、14、17、24d升高[(20.9±3.7)、(14.8±4.6)、(15.8±4.4)、(13.9±1.6)、(9.8±0.8)、(10.2±1.3)、(10.3±2.7) g](P＜0.05),R2组[(21.0±5.2)、(21.3±3.9)、(15.3±4.1)、(18.4±3.3)、(12.1±1.1)、(11.5±1.6)、(14.1±1.9)、(13.2±3.0)、(9.5±2.4)g]和R3组[(22.2±2.9)、(22.5±4.1)、(22.1±4.7)、(23.8±0.9)、(18.2±3.2)、(15.7±3.2)、(21.3±3.9)、(18.4±4.2)、(21.0±4.2) g]PWMT在术后所有时间点均升高(P＜0.05). 结论 术中罗哌卡因切口周围局部浸润可以抑制慢性术后疼痛.     

Simplified negative pressure wound therapy: clinical evaluation of an ultraportable,no‐canister system

The aim of this study was to evaluate a prototype negative pressure wound therapy (NPWT) system that has been developed to simplify NPWT for wounds at the lower end of the acuity scale. The new device has a single preset pressure of ?80 mmHg, is single use and operates without an exudate canister. The disposable NPWT system (PICO?) was tested in a prospective, non‐comparative, multicentre clinical trial to assess device functionality and clinical acceptance. Twenty patients were recruited for a maximum treatment period of 14 days. The NPWT devices were fitted with data log chips to enable longitudinal assessment of negative pressure and leak rates during therapy. Sixteen (80%) patients had closed surgical wounds, two (10%) patients had traumatic wounds and two (10%) patients received meshed split thickness skin grafts. The mean study duration was 10·7 days (range: 5–14 days) and the mean dressing wear time per individual patient was 4·6 days (range: 2–11). Fifty‐five percent of wounds had closed by the end of the 14‐day study or earlier, with a further 40% of wounds progressing to closure. Real‐time pressure monitoring showed continuous delivery of NPWT. Three cases are discussed representing different wound locations and different patient factors that can increase the risk of post‐surgical complications. Clinical studies of the disposable NPWT system confirmed the ability of the simplified single‐use device to function consistently over the expected wear time. The anticipated reduced costs, ease of use and increased mobility of patients using this system may enable NPWT benefits to be available to a greater proportion of patients.     

两种颌后切口入路治疗下颌骨髁突骨折的比较研究

目的：探讨两种颌后入路治疗下颌骨髁突颈骨折的治疗效果。方法：68例成人下颌骨中低位髁突颈骨折患者,随机分为A、B两组,经颌后入路,分别采用腮腺前缘入路及腮腺后下极入路,解剖复位髁突骨折行坚强内固定术。结果：68例患者均取得良好解剖复位,咬合关系恢复良好,无关节强直出现。A组2例出现面神经麻痹。B组1例出现涎瘘,4例出现面神经麻痹症状。结论：颌后入路可有效治疗髁突骨折,且腮腺前缘入路较腮腺后下极入路减少了手术并发症的发生。